These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Enhancement of vitreous clot lysis by urokinase: mode of action. Forrester JV; Edgar W; Millar W; Prentice CR; Williamson J Exp Eye Res; 1982 Jun; 34(6):895-907. PubMed ID: 6211365 [No Abstract] [Full Text] [Related]
23. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells. Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324 [TBL] [Abstract][Full Text] [Related]
24. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody. Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856 [No Abstract] [Full Text] [Related]
25. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity. Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083 [TBL] [Abstract][Full Text] [Related]
26. Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma. Tanaka N; Ogawa H; Kinjo M; Kohga S; Tanaka K Br J Cancer; 1982 Sep; 46(3):428-35. PubMed ID: 6751364 [TBL] [Abstract][Full Text] [Related]
27. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Idell S Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443 [TBL] [Abstract][Full Text] [Related]
28. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors. Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002 [TBL] [Abstract][Full Text] [Related]
29. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071 [TBL] [Abstract][Full Text] [Related]
30. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo]. Bode C; Eberle T; Runge M; Haber E; Kübler W Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723 [No Abstract] [Full Text] [Related]
31. [Low molecular weight heparin and high and low molecular weight urokinase in fibrinolysis in vivo]. Badimón L; Villaverde CA; Vidal M; Valdecasas FG Arch Farmacol Toxicol; 1979 Dec; 5(3):262-4. PubMed ID: 397803 [No Abstract] [Full Text] [Related]
32. Thromboplastic and fibrinolytic activities of ascites tumor cells of rats, with reference to their role in metastasis formation. Kohga S Gan; 1978 Aug; 69(4):461-70. PubMed ID: 710800 [TBL] [Abstract][Full Text] [Related]
34. Sustained fibrinolytic activity in the euglobulin fraction induced by concomitant administration of urokinase and dextran sulphate. Matsuo O; Kawaguchi T; Kosugi T; Mihara H Thromb Res; 1978 Dec; 13(6):1125-30. PubMed ID: 749265 [No Abstract] [Full Text] [Related]
35. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin]. Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687 [TBL] [Abstract][Full Text] [Related]
36. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Ishida T; Tanaka K Atherosclerosis; 1982 Aug; 44(2):161-74. PubMed ID: 7138618 [TBL] [Abstract][Full Text] [Related]
37. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase. Sumi H; Takada Y; Takada A Nihon Seirigaku Zasshi; 1977; 39(5):112-4. PubMed ID: 72149 [No Abstract] [Full Text] [Related]
38. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163 [TBL] [Abstract][Full Text] [Related]
39. Thrombin accelerating factor in various urokinase preparations. Takada A; Matsuda H; Urano T; Takada Y Thromb Res; 1979; 14(4-5):673-8. PubMed ID: 483262 [No Abstract] [Full Text] [Related]
40. Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits. Idell S; Mazar A; Cines D; Kuo A; Parry G; Gawlak S; Juarez J; Koenig K; Azghani A; Hadden W; McLarty J; Miller E Am J Respir Crit Care Med; 2002 Oct; 166(7):920-6. PubMed ID: 12359647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]